Profile data is unavailable for this security.
About the company
Kronos Bio, Inc. is a biopharmaceutical company. The Company is focused on developing therapeutics that target the deregulated transcription that causes cancer and other serious diseases. It is developing KB-0742, its internally discovered oral cyclin dependent kinase 9 (CDK9) inhibitor, for the treatment of MYC-amplified and others transcriptionally addicted solid tumors. It has initiated the Phase 2 portion of its Phase 1/2 clinical trial for KB-0742. It is also developing KB-9558, which inhibits the lysine acetyltransferase (KAT) domain of p300, a critical node of the IRF4 TRN. IRF4 is a key transcription factor driver in multiple myeloma and KB-9558 selectively targets its activity. Its scientific focus is on developing medicines that target deregulated transcription, the hallmark of cancer and other serious diseases. Using its Small Molecule Microarray (SMM) platform or other approaches, it can generate and advance small molecule starting points into drug development candidates.
- Revenue in USD (TTM)8.41m
- Net income in USD-102.85m
- Incorporated2017
- Employees58.00
- LocationKronos Bio Inc1300 S. El Camino Real, Suite 400SAN MATEO 94402United StatesUSA
- Phone+1 (650) 781-5200
- Fax+1 (302) 636-5454
- Websitehttps://www.kronosbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Xilio Therapeutics Inc | 2.36m | -65.53m | 47.91m | 73.00 | -- | 1.43 | -- | 20.33 | -2.11 | -2.11 | 0.067 | 0.7603 | 0.0259 | -- | -- | 32,287.67 | -71.92 | -- | -102.96 | -- | -- | -- | -2,780.27 | -- | -- | -166.76 | 0.00 | -- | -- | -- | 13.40 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 48.63m | 37.00 | -- | 1.13 | -- | 6.57 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| OncoCyte Corp | 1.02m | -36.80m | 48.82m | 43.00 | -- | 1.71 | -- | 47.72 | -4.26 | -4.26 | 0.1087 | 1.70 | 0.0126 | -- | 1.14 | 23,790.70 | -44.55 | -35.11 | -49.04 | -39.71 | 8.11 | -- | -3,532.75 | -2,373.36 | -- | -154.75 | 0.0212 | -- | 56.89 | -- | -34.84 | -- | 55.41 | -- |
| Aligos Therapeutics Inc | 7.97m | -75.74m | 50.19m | 68.00 | -- | 1.31 | -- | 6.30 | -25.99 | -25.99 | 1.89 | 10.70 | 0.0741 | -- | -- | 120,712.10 | -70.47 | -51.20 | -92.27 | -59.73 | -- | -- | -950.61 | -1,399.21 | -- | -- | 0.0031 | -- | 11.66 | -- | 8.71 | -- | -62.36 | -- |
| Unicycive Therapeutics Inc | 0.00 | -24.41m | 50.31m | 14.00 | -- | -- | -- | -- | -0.2843 | -0.2843 | 0.00 | 0.7193 | 0.00 | -- | -- | 0.00 | -68.77 | -218.20 | -118.93 | -609.54 | -- | -- | -- | -3,877.49 | -- | -- | 0.00 | -- | -29.02 | -- | -73.95 | -- | -- | -- |
| Kronos Bio Inc | 8.41m | -102.85m | 52.58m | 58.00 | -- | 0.4268 | -- | 6.25 | -1.75 | -1.75 | 0.1425 | 2.04 | 0.0396 | -- | -- | 135,661.30 | -48.41 | -35.47 | -53.26 | -37.14 | -- | -- | -1,222.83 | -7,975.76 | -- | -- | 0.00 | -- | -- | -- | 15.41 | -- | -8.78 | -- |
| BioVie Inc | 0.00 | -33.01m | 53.10m | 14.00 | -- | 1.19 | -- | -- | -7.92 | -7.92 | 0.00 | 2.51 | 0.00 | -- | -- | 0.00 | -106.51 | -330.64 | -176.17 | -875.72 | -- | -- | -- | -- | -- | -- | 0.2688 | -- | -- | -- | 34.32 | -- | -- | -- |
| Protara Therapeutics Inc | 0.00 | -40.69m | 53.22m | 26.00 | -- | 0.5782 | -- | -- | -3.19 | -3.19 | 0.00 | 4.46 | 0.00 | -- | -- | 0.00 | -41.35 | -37.02 | -43.70 | -38.29 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 38.71 | -- | -17.67 | -- |
| OS Therapies Inc | 0.00 | -6.55m | 53.73m | 4.00 | -- | -- | -- | -- | -0.3011 | -0.3011 | 0.00 | -1.32 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.9763 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Angion Biomedica Corp | 0.00 | -38.66m | 54.41m | 32.00 | -- | -- | -- | -- | -4.83 | -4.83 | 0.00 | -0.161 | 0.00 | -- | -- | 0.00 | -144.89 | -105.91 | -202.49 | -331.69 | -- | -- | -- | -712.81 | -- | -- | -- | -- | -100.00 | -- | 9.31 | -- | -- | -- |
| Gain Therapeutics Inc | 0.00 | -21.60m | 55.41m | 29.00 | -- | 4.64 | -- | -- | -1.33 | -1.33 | 0.00 | 0.4682 | 0.00 | -- | -- | 0.00 | -115.33 | -- | -170.44 | -- | -- | -- | -- | -13,827.07 | -- | -- | 0.0396 | -- | -60.62 | 21.77 | -26.59 | -- | 13.96 | -- |
| Prenetics Global Ltd | 22.50m | -45.63m | 55.64m | 320.00 | -- | 0.2573 | -- | 2.47 | -3.79 | -4.14 | 1.86 | 17.70 | 0.0875 | 3.23 | 4.63 | 70,304.00 | -18.52 | -- | -22.89 | -- | 52.31 | -- | -211.67 | -- | 1.98 | -8.67 | 0.0122 | -- | 65.17 | -- | 75.91 | -- | -- | -- |
| Shattuck Labs Inc | 4.12m | -85.28m | 56.32m | 75.00 | -- | 0.5091 | -- | 13.66 | -1.85 | -1.85 | 0.0883 | 2.32 | 0.029 | -- | -- | 54,986.67 | -60.08 | -29.14 | -66.66 | -32.42 | -- | -- | -2,067.99 | -565.33 | -- | -- | 0.00 | -- | 154.14 | -40.62 | 14.37 | -- | -19.15 | -- |
| Immuneering Corp | 0.00 | -56.07m | 56.34m | 66.00 | -- | 0.8497 | -- | -- | -1.91 | -1.91 | 0.00 | 2.24 | 0.00 | -- | -- | 0.00 | -55.52 | -- | -59.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -100.00 | -- | -5.86 | -- | -- | -- |
Data as of Nov 12 2024. Currency figures normalised to Kronos Bio Inc's reporting currency: US Dollar USD
19.51%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 30 Jun 2024 | 1.91m | 3.17% |
| Millennium Management LLCas of 30 Jun 2024 | 1.86m | 3.08% |
| Partners Capital Investment Group LLPas of 30 Sep 2024 | 1.61m | 2.67% |
| Wildcat Capital Management LLCas of 30 Sep 2024 | 1.30m | 2.15% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.23m | 2.04% |
| Mariner LLCas of 30 Jun 2024 | 1.04m | 1.73% |
| Invus Public Equities Advisors LLCas of 30 Jun 2024 | 842.95k | 1.40% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 764.13k | 1.27% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 654.43k | 1.09% |
| Acuitas Investments LLCas of 30 Sep 2024 | 554.50k | 0.92% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
